Abstract
A series of hetaryl imidazoles with VEGF receptors I and II inhibitory activities was subjected to QSAR analysis employing molecular descriptors calculated using QSAR software Dragon. Quantitative models of good statistical significance were formulated for both the activities through stepwise multiple linear regression using the method of least squares and the generated models were evaluated for predictive ability employing cross validation procedure following a leave-one-out scheme. The interpretation of the QSAR models indicated that VEGF receptor II inhibitory activity of the title compounds is influenced by the number of hydrogen acceptor atoms and benzyl groups in the molecule whereas VEGF receptor I inhibitory activity is influenced by benzyl and aromatic functionalities and dipoles in the molecule. Furthermore, the QSAR model derived for Model for VEGF receptor II (cell based ELISA) inhibitory activity highlighted that electron withdrawing groups are beneficial and lipophilic moieties are detrimental to the activity.
Keywords: Hetaryl imidazoles, QSAR, VEGF receptor inhibitors, Dragon software
Medicinal Chemistry
Title: QSAR Study on Hetaryl Imidazoles: A Novel Dual Inhibitor of VEGF Receptors I and II
Volume: 6 Issue: 1
Author(s): Asha Patel, C. Karthikeyan, N.S.H.N. Moorthy and P. Trivedi
Affiliation:
Keywords: Hetaryl imidazoles, QSAR, VEGF receptor inhibitors, Dragon software
Abstract: A series of hetaryl imidazoles with VEGF receptors I and II inhibitory activities was subjected to QSAR analysis employing molecular descriptors calculated using QSAR software Dragon. Quantitative models of good statistical significance were formulated for both the activities through stepwise multiple linear regression using the method of least squares and the generated models were evaluated for predictive ability employing cross validation procedure following a leave-one-out scheme. The interpretation of the QSAR models indicated that VEGF receptor II inhibitory activity of the title compounds is influenced by the number of hydrogen acceptor atoms and benzyl groups in the molecule whereas VEGF receptor I inhibitory activity is influenced by benzyl and aromatic functionalities and dipoles in the molecule. Furthermore, the QSAR model derived for Model for VEGF receptor II (cell based ELISA) inhibitory activity highlighted that electron withdrawing groups are beneficial and lipophilic moieties are detrimental to the activity.
Export Options
About this article
Cite this article as:
Patel Asha, Karthikeyan C., Moorthy N.S.H.N. and Trivedi P., QSAR Study on Hetaryl Imidazoles: A Novel Dual Inhibitor of VEGF Receptors I and II, Medicinal Chemistry 2010; 6 (1) . https://dx.doi.org/10.2174/157340610791208736
DOI https://dx.doi.org/10.2174/157340610791208736 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Advancements in the Treatment and Repair of Tendon Injuries
Current Tissue Engineering (Discontinued) Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Current Topics in Medicinal Chemistry The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Ethiopathogenesis, Diagnosis and Prevention of Vascular Calcification in End Stage Renal Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Recent Inventions on Receptor Tyrosine Kinase RET Modulation
Recent Patents on Biotechnology Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Current Pharmaceutical Design On Chemical Structures with Potent Antiepileptic/Anticonvulsant Profile
Mini-Reviews in Medicinal Chemistry Overcoming hERG Affinity in the Discovery of Maraviroc; A CCR5 Antagonist for the Treatment of HIV
Current Topics in Medicinal Chemistry Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Current Pharmaceutical Design Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews Irreversible Protein Kinase Inhibitors
Current Medicinal Chemistry Hypoxia Inducible Factor Stabilization As a Novel Strategy to Treat Anemia
Current Medicinal Chemistry Current Applications of Artificial Neural Networks in Biochemistry with Emphasis on Cancer Research
Current Biochemical Engineering (Discontinued) Recent Progress of Src SH2 and SH3 Inhibitors as Anticancer Agents
Current Medicinal Chemistry Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Evaluation of a Polymer-Lipid-Polymer System Utilising Hybrid Nanoparticles of Dapsone as a Novel Antiacne Agent
Current Drug Therapy Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design Designing Peptidomimetics
Current Topics in Medicinal Chemistry